MURA muraloncology.com Gross Profitability

MURA (Mural Oncology plc) - company brandmark

A lack of pricing power due to venture financing during the development stage determines the cost structure, which is clearly evident in the gross margin history of Mural Oncology plc (MURA). The value 0.00 becomes the new metric value, capturing current profitability. Business stability is guaranteed by the non-cyclical nature of oncology research, while drug delivery reliability is ensured by a specialized cold chain, minimizing macroeconomic risks for Mural Oncology plc (MURA).

MURA (muraloncology.com) Gross Profitability history from 02/21/2024 to 12/20/2025

Financial and market metric breakdowns for Mural Bio (MURA)

- market value and analyst target forecast:
Basic company analysis:MURA muraloncology.com
Brand item of Mural Oncology PLC

Gross margin determines the efficiency of covering direct production costs, demonstrating the profit share from each unit of revenue before accounting for operating expenses. An analysis of the monthly gross margin for Mural Oncology plc (MURA) allows for an assessment of financial stability during the development of immuno-oncology drugs, where the diversification of interleukin research mitigates risks, turning the indicator's stability into a confirmation of pipeline viability for the investor.

Main competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|UroGen Pharma - Return on Gross Profit|Gross Profit Rate BCAX|PSNL - Gross Profitability|Return on Sales by Gross Profit Erasca Oncology ERAS|delcath.com (DCTH) - Gross Profitability|Y-mAbs Therapeutics - Gross Profit Rate|AURA (Aura Biosciences Inc) - Gross Margin|Gross Profit Margin candeltx.com CADL|Gross Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Gross Profit Rate|Gross Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Gross Profitability|TuHURA Biosciences Inc. - Gross Margin|TARA - Gross Margin|FATE (Fate Therapeutics) - Return on Gross Profit|Return on Gross Profit Aadi Bioscience, Inc.|Return on Gross Profit TCRX|Gross Profitability CSBR|Gross Margin XBIT|Return on Sales by Gross Profit CEL-SCI Corp.|Gross Profitability ostherapies.com OSTX|RADX: Gross Return on Sales|ARTV: Return on Gross Profit|ANL (Adlai Nortye) - Gross Return on Sales|Veru (VERU) - Gross Profitability|Return on Gross Profit Tempest Therapeutics Inc|Gross Profitability Xilio Therapeutics|Gross Return on Sales RENB (Renovaro Inc.)|Gross Margin KAPA|Return on Sales by Gross Profit OnKure Therapeutics, Inc.|Gross Margin GDTC (w2.cytomed.sg)|CRIS - Return on Gross Profit|Apollomics - Gross Margin|Tharimmune Corp (THAR) - Return on Gross Profit|ADVB: Gross Margin|Return on Gross Profit Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Gross Margin|Gross Return on Sales SBFM (Sunshine Biopharma)|Gross Profitability Xenetic Bio (XBIO)|Gross Profitability SLRX (Salarius Pharma)|Kitov Pharma - Return on Gross Profit|American Oncology Network (AONC) - Gross Profit Margin|BeiGene - Gross Margin|Checkpoint Therapeutics, Inc. (CKPT) - Return on Gross Profit|ELEV (Elevation Oncology, Inc.) - Return on Gross Profit|iCAD Inc. - Gross Profit Rate|Return on Gross Profit IKNA|Gross Margin notablelabs.com|Return on Gross Profit VIRX (Viracta Therapeutics Inc.)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit